Key Highlights
● SELLAS priced a $150 million offering at $13.00 a share.
● The stock closed at $14.86, still above the offering price.
● Phase 3 REGAL data showed a hazard ratio of 0.59 in AML.
● Underwriters have an option to buy up to $22.5 million more shares.
SELLAS Life Sciences (NASDAQ:SLS) shares sank to $14.86 on Thursday after the cancer drug developer priced a $150 million stock offering at $13, below the prior close, following an explosive rally on positive late-stage trial data.
The offering
SELLAS Life Sciences priced a $150 million public offering of common stock at $13.00 a share, below its previous closing price, according to market data. JPMorgan (NYSE:JPM) and TD Cowen ran the books, and the underwriters have an option to buy up to $22.5 million of additional shares.
Shares sank on Thursday, November 19, closing at $14.86, still above the offering price. Premarket readings had shown a deeper drop.
The run that came before
The offering followed one of the most dramatic rallies of the week. On Tuesday, November 17, SELLAS reported positive topline data from its Phase 3 REGAL trial of galinpepimut-S, or GPS, in acute myeloid leukaemia. The company reported that the trial showed a hazard ratio of 0.59 for risk of death, with a p-value of 0.035, and median overall survival of 24.0 months versus 14.7 months.
The stock more than doubled on Tuesday and more than doubled again the following day, compounding into an enormous move in two sessions.
Galinpepimut-S is an experimental immunotherapy being developed for acute myeloid leukaemia, a fast-moving cancer of the blood and bone marrow. The REGAL study measured whether it could extend survival compared with the control group. The data released on Tuesday were topline results; fuller details are typically presented later at medical meetings or in regulatory submissions.
Why companies sell stock after big gains
For a clinical-stage biotech, a rally like this week's creates an opportunity to raise Capital on far better terms than before. Companies developing drugs need substantial funding to complete regulatory filings, prepare Manufacturing and build commercial operations. Issuing new shares after a sharp rise means fewer shares need to be sold to raise a given amount of money.
For existing shareholders, though, an offering adds to the number of shares outstanding, and it is typically priced at a discount to the market to attract buyers. That combination often leads to a pullback on the day an offering is priced, as the market adjusts to the new Supply and the discounted price. Thursday's decline fits that familiar pattern.
A heavy day for markets
The offering hit a market already in retreat. The Nasdaq Composite fell 550.69 points to 23,879.20, its lowest close since April, according to market data. The S&P 500 dropped 147.80 points for a sixth straight decline, and the Dow Jones Industrial Average fell 1,101.11 points to close below 50,000. Health care was among the weaker sectors, and small caps underperformed, with the Russell 2000 down 59.20 points. The Cboe Volatility index rose 3.88 points to 28.44, and weekly jobless claims rose to 203,000, above expectations.
What to watch
The next steps are the closing of the offering and whether underwriters exercise their option for additional shares. Beyond financing, investors will look for SELLAS to outline its regulatory plans for galinpepimut-S, the timing of any submission and fuller presentation of the REGAL data. How the stock trades relative to the $13 offering price in coming sessions will be a closely watched marker of Demand for the newly issued stock.






Please wait processing your request...